NO20083033L - Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler - Google Patents

Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler

Info

Publication number
NO20083033L
NO20083033L NO20083033A NO20083033A NO20083033L NO 20083033 L NO20083033 L NO 20083033L NO 20083033 A NO20083033 A NO 20083033A NO 20083033 A NO20083033 A NO 20083033A NO 20083033 L NO20083033 L NO 20083033L
Authority
NO
Norway
Prior art keywords
sulfamide derivatives
neuroprotective agents
treating
formula
benzofused heterocyclic
Prior art date
Application number
NO20083033A
Other languages
English (en)
Norwegian (no)
Inventor
Allen B Reitz
Virginia L Smith-Swintosky
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37951698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20083033(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20083033L publication Critical patent/NO20083033L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
NO20083033A 2005-12-19 2008-07-04 Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler NO20083033L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75149405P 2005-12-19 2005-12-19
US11/612,146 US20070155823A1 (en) 2005-12-19 2006-12-18 Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
PCT/US2006/048451 WO2007075698A2 (en) 2005-12-19 2006-12-19 Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents

Publications (1)

Publication Number Publication Date
NO20083033L true NO20083033L (no) 2008-09-16

Family

ID=37951698

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083033A NO20083033L (no) 2005-12-19 2008-07-04 Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler

Country Status (23)

Country Link
US (1) US20070155823A1 (pt)
EP (1) EP1968571B1 (pt)
JP (1) JP5190373B2 (pt)
KR (1) KR20080089405A (pt)
AT (1) ATE536182T1 (pt)
AU (1) AU2006331783A1 (pt)
BR (1) BRPI0620060A2 (pt)
CA (1) CA2634088A1 (pt)
CR (1) CR10171A (pt)
CY (1) CY1112444T1 (pt)
DK (1) DK1968571T3 (pt)
EA (1) EA016628B1 (pt)
ES (1) ES2375845T3 (pt)
HR (1) HRP20120018T1 (pt)
IL (1) IL192106A0 (pt)
MY (1) MY149175A (pt)
NO (1) NO20083033L (pt)
NZ (1) NZ569041A (pt)
PL (1) PL1968571T3 (pt)
PT (1) PT1968571E (pt)
RS (1) RS52220B (pt)
SI (1) SI1968571T1 (pt)
WO (1) WO2007075698A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20080012360A (ko) * 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
EA200870556A1 (ru) * 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
BRPI0911772A2 (pt) * 2008-04-29 2017-06-27 Nsab Filial Af Neurosearch Sweden Ab Sverige composto, composição farmacêutica, e, uso do composto.
WO2009133109A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
CN102015674B (zh) * 2008-04-29 2014-10-29 Nsab神经研究瑞典公司分公司 多巴胺神经传递调节剂
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
TWI406596B (zh) 2008-06-30 2013-08-21 Green Solution Tech Co Ltd 發光二極體驅動電路、發光二極體驅動控制單元及其電晶體開關模組
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
EP2760851A1 (en) 2011-09-29 2014-08-06 Janssen Pharmaceutica, N.V. Process for the preparation of sulfamide derivatives
KR20140082762A (ko) 2011-09-29 2014-07-02 얀센 파마슈티카 엔.브이. 설파미드 유도체의 개선된 제조 방법
LT2865663T (lt) * 2012-06-21 2017-07-10 Eisai R&D Management Co., Ltd. Naujas indansulfamido darinys
MX2020009100A (es) 2018-03-20 2020-12-03 Eisai R&D Man Co Ltd Agente de tratamiento de la epilepsia.

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2527861A (en) * 1948-05-07 1950-10-31 Monsanto Chemicals Mono alkyl sulfamides
BE636655A (pt) * 1962-09-14
US3318952A (en) * 1964-01-22 1967-05-09 Sandoz Ag Dibenzylsulfamides
US3383414A (en) * 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3621096A (en) * 1969-04-03 1971-11-16 Univ North Carolina Antidepressant method and composition for same comprising a tricyclic antidepressant and a thyroid hormone
US5212326A (en) * 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
FR2479825A1 (fr) * 1980-04-04 1981-10-09 Fabre Sa Pierre Benzodioxanne 1,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5194446A (en) * 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
AU651244B2 (en) * 1991-09-19 1994-07-14 Mcneilab, Inc. Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) * 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
CA2216648A1 (en) * 1995-02-15 1996-08-22 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
JP3235448B2 (ja) * 1995-03-24 2001-12-04 ダイソー株式会社 １，４−ベンゾジオキサン誘導体の製法
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
WO1997019682A1 (en) * 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
RU2214241C2 (ru) * 1996-06-28 2003-10-20 Орто-Макнейл Фармасьютикал, Инк. Способ лечения ожирения и способ индуцирования потери веса у млекопитающих
AU4078897A (en) * 1996-08-23 1998-03-06 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
AU9021298A (en) * 1997-08-15 1999-03-08 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
WO2000042996A2 (en) * 1999-01-19 2000-07-27 Ortho-Mcneil Pharmaceutical, Inc. Use of anticonvulsant derivatives for treating cluster headaches
ATE294577T1 (de) * 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
JP2002541199A (ja) * 1999-04-08 2002-12-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 脂質を下げることに有用な抗痙攣薬誘導体
JP2003521471A (ja) * 1999-04-08 2003-07-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 慢性神経変性疾患を処置することに有用な抗痙攣薬誘導体
EA006598B1 (ru) * 1999-08-20 2006-02-24 Орто-Макнейл Фармасьютикал, Инк. Композиция, содержащая трамадол и противосудорожное лекарственное средство
US6322503B1 (en) * 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
US6852701B2 (en) * 2000-07-07 2005-02-08 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for preventing the development of Type II diabetes mellitus and Syndrome X
MXPA03001001A (es) * 2000-08-02 2003-10-14 Johnson & Johnson Derivados anticonvulsionantes utiles para el tratameinto de la depresion.
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US6852738B2 (en) * 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
MY142329A (en) * 2004-08-24 2010-11-15 Janssen Pharmaceutica Nv Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents.
US20060276528A1 (en) * 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
RU2007139543A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные бензодиоксана и бензодиоксолана и их применение
KR20080012360A (ko) * 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
EA200870556A1 (ru) * 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
US20070293476A1 (en) * 2006-05-19 2007-12-20 Smith-Swintosky Virginia L Co-therapy for the treatment of epilepsy and related disorders
US20090182141A1 (en) * 2008-01-07 2009-07-16 Ahmed Abdel-Magid Process for the preparation of sulfamide derivatives
US20090247618A1 (en) * 2008-03-26 2009-10-01 Ballentine Scott A Process for preparation of benzo-fused heteroaryl derivatives
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
BRPI0915890A2 (pt) * 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives

Also Published As

Publication number Publication date
PT1968571E (pt) 2012-02-01
EP1968571B1 (en) 2011-12-07
RS52220B (sr) 2012-10-31
DK1968571T3 (da) 2012-02-27
MY149175A (en) 2013-07-31
US20070155823A1 (en) 2007-07-05
NZ569041A (en) 2011-04-29
CY1112444T1 (el) 2015-12-09
ATE536182T1 (de) 2011-12-15
CA2634088A1 (en) 2007-07-05
EP1968571A2 (en) 2008-09-17
HRP20120018T1 (hr) 2012-01-31
JP5190373B2 (ja) 2013-04-24
BRPI0620060A2 (pt) 2011-11-01
IL192106A0 (en) 2009-08-03
HK1124544A1 (en) 2009-07-17
EA016628B1 (ru) 2012-06-29
KR20080089405A (ko) 2008-10-06
PL1968571T3 (pl) 2012-04-30
AU2006331783A1 (en) 2007-07-05
ES2375845T3 (es) 2012-03-06
WO2007075698A3 (en) 2007-08-16
CR10171A (es) 2009-01-16
SI1968571T1 (sl) 2012-03-30
EA200870087A1 (ru) 2009-12-30
WO2007075698A2 (en) 2007-07-05
JP2009520031A (ja) 2009-05-21

Similar Documents

Publication Publication Date Title
NO20083033L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater som neurobeskyttende midler
WO2007095618A3 (en) Benzo-fused heterocycle sulfamide derivatives for the treatment of migraine
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007095613A3 (en) Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
NO20083004L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av stoffmisbrukavhengighet
NO20072665L (no) Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser
ATE384058T1 (de) Thiazolderivate
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
IL192103A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
BRPI0921692A2 (pt) composto carbamato ou o sal do mesmo
SI1973540T1 (sl) Uporaba benzokondenziranih heterocikličnih sulafamidnih derivatov za zdravljenje bolečine
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
MY145823A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
WO2007095611A3 (en) Use of benzo-fused heteroaryl sulfamide derivatives for the treatment of migraine
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
UA96747C2 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных как нейропротективных агентов
UA95094C2 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
WO2007117272A3 (en) Methods for treatment of hemorrhagic shock and related disorders
UA100552C2 (ru) Применение гетероциклических бензопроизводных сульфамида для лечения тревожных расстройств
ATE502947T1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren
TH94294A (th) การใช้อนุพันธ์เบนโซ-ฟิวเซด เฮเทอโรไซเคิล ซัลฟาไมด์ เป็นสารป้องกันการทำลายเซลล์ประสาทในสมอง
UA97106C2 (ru) Применение производных бензоконденсированного гетероциклического сульфамида для лечения злоупотребления психоактивным веществом и аддикции
TW200738231A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of migraine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application